TY - JOUR T1 - From loss to recovery: how to effectively assess chemosensory impairments during COVID-19 pandemic JF - medRxiv DO - 10.1101/2021.03.25.21254253 SP - 2021.03.25.21254253 AU - Cinzia Cecchetto AU - Antonella Di Pizio AU - Federica Genovese AU - Orietta Calcinoni AU - Alberto Macchi AU - Andreas Dunkel AU - Kathrin Ohla AU - Sara Spinelli AU - Michael C. Farruggia AU - Paule V. Joseph AU - Anna Menini AU - Elena Cantone AU - Caterina Dinnella AU - Maria Paola Cecchini AU - Anna D’Errico AU - Carla Mucignat-Caretta AU - Valentina Parma AU - Michele Dibattista Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/03/26/2021.03.25.21254253.abstract N2 - Chemosensory impairments have been established as a specific indicator of COVID-19. They affect most patients and may persist long past the resolution of respiratory symptoms, representing an unprecedented medical challenge. Since the SARS-CoV-2 pandemic started, we now know much more about smell, taste, and chemesthesis loss associated with COVID-19. However, the temporal dynamics and characteristics of recovery are still unknown. Here, capitalizing on data from the Global Consortium for Chemosensory Research (GCCR) crowdsourced survey, we assessed chemosensory abilities after the resolution of respiratory symptoms in participants diagnosed with COVID-19 during the first wave of the pandemic in Italy. This analysis led to the identification of two patterns of chemosensory recovery, limited (partial) and substantial, which were found to be associated with differential age, degrees of chemosensory loss, and regional patterns. Uncovering the self-reported phenomenology of recovery from smell, taste, and chemesthetic disorders is the first, yet essential step, to provide healthcare professionals with the tools to take purposeful and targeted action to address chemosensory disorders and its severe discomfort.Competing Interest StatementThe authors have declared no competing interest.Funding StatementCC was supported by a grant from MIUR (Dipartimenti di Eccellenza DM 11/05/2017 n. 262) to the Department of General Psychology. FG is supported by NIH/NIDCD grant R21DC018358. PVJ is supported by the National Institute of Alcohol Abuse and Alcoholism and the National Institute of Nursing Research. PVJ is also supported by the Office of Workforce Diversity, National Institutes of Health, and the Rockefeller University Heilbrunn Nurse Scholar Award.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The online survey was approved by the Office of Research Protections of The Pennsylvania State University (STUDY00014904) in accordance with the revised Declaration of Helsinki.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe preprocessed datasets and the R code for the reported analyses can be found on the Open Science Framework database (https://osf.io/vun72/) ER -